readthroughSign in
Nov 16, 2026Regulatory decisionUpdated

Alexion's Klygefa wins US FDA approval for generalised myasthenia gravis, days after EU clearance

The FDA approved the once-weekly subcutaneous C5 inhibitor for AChR antibody-positive adult gMG, with the agency's review record dated 13 November 2026.

Alexion, AstraZeneca Rare Disease, announced on 16 November 2026 that the US Food and Drug Administration had approved Klygefa (gefurulimab) for generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. The approval covers adults who are anti-acetylcholine receptor (AChR) antibody positive.1 FDA records show the approval under BLA761488 as a Type 1 new molecular entity, with a submission status date of 2026-11-13 and a label dated 20261113, sponsored by Alexion Pharm.

The US clearance follows the European Commission's approval of Klygefa for the same adult gMG population, also announced 16 November 2026. The FDA's decision was based on positive results from the pivotal PREVAIL Phase III trial, in which Klygefa met its primary endpoint of improvement from baseline in Myasthenia Gravis Activities of Daily Living total score at week 26 compared to placebo, with a treatment difference of -1.6 (95% CI: -2.4, -0.8), p<0.0001.1 Clinical improvement was observed as early as week one.1

PREVAIL enrolled 260 patients from 20 countries across North America, Europe, Asia and the Pacific region, with participants required to have a confirmed myasthenia gravis diagnosis at least three months before screening and a positive AChR autoantibody test.1 Dosing involved a single weight-based loading dose on Day 1, followed by weight-based maintenance dosing starting Day 8 and once weekly thereafter.1

The company said Klygefa was generally well-tolerated, with a safety profile consistent with prior C5 inhibitor trials; treatment-emergent adverse event rates were similar between Klygefa and placebo arms, mostly mild to moderate, with injection site reactions (12%), back pain (8%) and vomiting (5%) most common.1

Klygefa is now approved in the EU, Japan and other countries for certain adults with gMG, with regulatory submissions based on PREVAIL under review in China and additional countries.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.